The Effect of Astaxanthin on Endometriosis Patients

The Effect of Astaxanthin on the Expression of Genes Involved in Wnt /ß-catenin Pathway in the Eutopic Endometrium and Inflammatory Factors Downstream of the NF-?B Pathway in the Serum of Women with Endometriosis Candidate for Assisted Reproductive Techniques

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220625055274N1

Enrollment

Registered

2022-09-03

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis, unspecified

Interventions

Intervention 1: Astaxanthin group: 1. Astaxanthin consumption: participants will take 6 mg of Astaxanthin daily (1 capsule containing 6 mg Astaxanthin) for 12 weeks. Intervention 2: Placebo group: Pla

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with infertility due to endometriosis stage III or IV confirmed by ultrasound, laparoscopy, or histopathological examination 20 to 40 years old 18.5 < BMI <30 kg / m2 With regular menstrual cycles Not taking any hormonal medicine, hormonal contraception, or IUD for 3 months before the first biopsy No pregnancy or breastfeeding since 3 months before the first biopsy Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Autoimmune defects, cancer, and diabetes Chronic infectious diseases Any anatomical abnormalities in the uterine cavity such as fibroids and polyps Pregnancy during the intervention Taking hormonal drugs during the intervention

Design outcomes

Primary

Measure	Time frame
Level of inflammatory cytokines, expression of Wnt/ ß-catenin pathway genes (ß-catenin, GSK-3b, DKK-1, and WNT7a), expression of phosphorylated and dephosphorylated ß-catenin protein. Timepoint: Before and 12 weeks after the intervention. Method of measurement: ELISA, Real-Time PCR, Western Blot.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fardin Amidi

Tehran University of Medical Sciences

famidi@tums.ac.ir+98 21 6405 3411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026